Our passion is to revolutionise the purification industry with cutting edge technology
We established Purius in 2016 to exploit opportunities within the biopharmaceutical sector, specifically delivering a solution to reduce manufacturing costs and increase throughput. To do so, we have established a novel technological process called ‘zero step purification’. The purification stage of pharmaceutical drug production is currently resource-inefficient. Current industry processes involve the use of resin, filters and other consumables, the use of which are no longer required when using our process.
We estimate that our platform can eliminate up to 60% of downstream processing costs (DSP). We have identified through extensive market research that DSP is the bottleneck costing an average of 55%-80% of cost of goods (COGs).
Emerging markets such as biosimilars are growing fast but under enormous cost pressure due to the significant costs associated with the current drug refinement processes.
We are keen to disrupt the market with our novel approach that offers significant cost savings and productivity improvements.
We are a team of expert scientists and engineers from the biochemical sector who have worked together for more than 10 years, and have more than 30 years of collective experience. Our expertise ranges from regulatory aspects and downstream purification to molecular biology and wider knowledge of the biopharmaceutical industry. And we are still learning.
Co-Founder & CEO
Purification Process Engineer
MEng Biochemical Engineering
Lead Inventor: 3 Patents pending
Co-Founder & CTO
PhD Biochemical Engineering
To contact us, please leave your details along with your message. We will be happy to answer any further questions or queries you may have.
We look forward to hearing from you.
BIOLOGICS PURIFICATION SPECIALISTS
WHAT DOES OUR PRODUCT ACHIEVE?
REDUCES TIME AND COST
ELIMINATES HIGH CONSUMABLE USAGE
Substantially lowers usage of the primary cost drivers in biopharmaceutical production
Achieves near one vessel operation and releases scalability
Shorter, simpler and cheaper route to biologics manufacturing
Co-Founder & Investing Partner